Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 277,924,800
  • Shares Outstanding, K 2,532,806
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.39
  • Price/Sales 4.61
  • Price/Cash Flow 35.96
  • Price/Book 6.35
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 28.36% ( -0.11%)
  • Historical Volatility 17.54%
  • IV Percentile 99%
  • IV Rank 99.14%
  • IV High 28.48% on 10/10/24
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.33
  • Today's Volume 21,338
  • Volume Avg (30-Day) 35,428
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 412,058
  • Open Int (30-Day) 378,747

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.63
  • Number of Estimates 8
  • High Estimate 1.91
  • Low Estimate 1.42
  • Prior Year 2.13
  • Growth Rate Est. (year over year) -23.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
107.81 +1.78%
on 10/08/24
119.38 -8.08%
on 09/18/24
-4.98 (-4.34%)
since 09/11/24
3-Month
107.81 +1.78%
on 10/08/24
129.93 -15.55%
on 07/12/24
-19.24 (-14.92%)
since 07/11/24
52-Week
99.14 +10.68%
on 10/19/23
134.63 -18.50%
on 06/25/24
+6.27 (+6.06%)
since 10/11/23

Most Recent Stories

More News
2 Incredibly Cheap Big Pharma Stocks to Buy Now

There's doubtlessly some coming uncertainty for both, but the prices are right.

MRK : 109.73 (+0.30%)
PFE : 29.16 (-0.61%)
BMY Buoyed by Recent Regulatory Updates: How to Play the Stock?

Last week, Bristol Myers BMY obtained FDA approval for a label expansion of its blockbuster immuno oncology drug Opdivo (nivolumab).The FDA approved Opdivo as a perioperative treatment regimen for adults...

MRK : 109.73 (+0.30%)
PFE : 29.16 (-0.61%)
BMY : 52.20 (-0.38%)
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

VKTX : 65.84 (+5.43%)
SMMT : 19.95 (+7.20%)
MRK : 109.73 (+0.30%)
Is It Time to Buy September's Worst-Performing Dow Jones Stocks?

They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices.

JPM : 222.29 (+4.44%)
MRK : 109.73 (+0.30%)
$DOWI : 42,863.86 (+0.97%)
BA : 151.02 (+3.00%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

NetworkNewsWire Editorial Coverage : Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address...

ANVS : 7.93 (-0.88%)
JNJ : 161.46 (+0.59%)
MRK : 109.73 (+0.30%)
NVS : 116.22 (+1.23%)
GSK : 38.83 (-0.97%)
3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally

Check out these three bargain stock that missed out on the rally to market highs, but have reasons for optimism going forward.

AMAT : 205.06 (+0.54%)
MRK : 109.73 (+0.30%)
LRCX : 82.89 (+1.01%)
ADBE : 495.42 (-1.62%)
Stock Market News for Oct 4, 2024

U.S. stock markets closed lower on Thursday after a choppy session. Market participants were mostly remained sidelined before the release of the key job data for September. Crude oil prices spiked following...

MRK : 109.73 (+0.30%)
Could Summit Therapeutics Become the Next Merck?

Recent developments are forcing comparisons between these two drugmakers.

SMMT : 19.95 (+7.20%)
MRK : 109.73 (+0.30%)
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

ANVS : 7.93 (-0.88%)
JNJ : 161.46 (+0.59%)
MRK : 109.73 (+0.30%)
NVS : 116.22 (+1.23%)
GSK : 38.83 (-0.97%)
Screener Results Revealed: Bear Call Spread Opportunities for September 30th

Let’s take a look at Barchart’s Bear Call Spread Screener for September 30th:

COP : 110.49 (-1.22%)
INTC : 23.56 (+1.46%)
MRK : 109.73 (+0.30%)
SLB : 44.78 (+0.40%)
MU : 106.92 (+1.16%)
NKE : 82.15 (+0.06%)
DIS : 94.13 (+1.23%)
CRWD : 320.21 (+1.68%)
GOOGL : 163.24 (+0.72%)
WFC : 60.99 (+5.61%)
SMCI : 47.80 (+2.86%)
SNOW : 124.03 (+0.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 112.48
2nd Resistance Point 111.20
1st Resistance Point 110.46
Last Price 109.73
1st Support Level 108.45
2nd Support Level 107.17
3rd Support Level 106.43

See More

52-Week High 134.63
Fibonacci 61.8% 121.07
Fibonacci 50% 116.89
Fibonacci 38.2% 112.70
Last Price 109.73
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar